Multiple myeloma patients are better equipped to halt progression of this blood cancer if treated with lenalidomide, or Revlimid®, following a stem cell transplant.

( ) ( ) ( ) SOUTH SAN FRANCISCO, Calif., May 16, 2012 /PRNewswire/ -- Onyx Pharmaceuticals, Inc.

PALO ALTO, Calif., May 15, 2012 /PRNewswire/ -- Telik, Inc. (Nasdaq: TELK) today announced two publications in the Journal of Hematology & Oncology.

PALO ALTO, Calif., May 9, 2012 /PRNewswire/ -- Telik, Inc. (Nasdaq: TELK) today reported financial results for the first quarter ended March 31, 2012.

A Phase 2 Multicenter Study of Two Extended Dosing Schedules of Oral Ezatiostat in Low to Intermediate-1 Risk Myelodysplastic Syndrome (MDS)," Raza, A., et al., Cancer, doi: 10.1002/cncr.26469, September 1, 2011. TELINTRA is the first GST P1-1 inhibitor shown to cause clinically significant and sustained reduction in red blood cell transfusions, transfusion independence and multilineage responses in MDS patients. Publication of a Report of Complete Response of G-CSF Resistent Severe Idiopathic Chronic Neutropenia Following Treatment with TELINTRA in the Journal of Hematology & Oncology entitled "Oral ezatiostat HCl (Telintra®, TLK199) and Idiopathic Chronic Neutropenia (ICN): A case report of complete response of a patient with G-CSF resistant severe chronic idiopathic neutropenia following treatment with Telintra